Opdivo delivers superior five-year survival results in renal cell carcinoma

Bristol-Myers Squibb said that a five-year follow-up of the phase 3 CheckMate -025 study showed that Opdivo (nivolumab) delivered superior five-year survival results in patients with renal cell carcinoma (RCC).